Cidara Therapeutics EBITDA Margin 2014-2022 | CDTX

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Cidara Therapeutics (CDTX) over the last 10 years. The current EBITDA margin for Cidara Therapeutics as of September 30, 2022 is .
Cidara Therapeutics EBITDA Margin Historical Data
2022-09-30 $0.06B $-0.03B -54.10%
2022-06-30 $0.03B $-0.07B -251.85%
2022-03-31 $0.05B $-0.04B -81.48%
2021-12-31 $0.05B $-0.04B -89.80%
2021-09-30 $0.05B $-0.05B -100.00%
2021-06-30 $0.04B $-0.05B -109.76%
2021-03-31 $0.01B $-0.07B -672.73%
2020-12-31 $0.01B $-0.07B -583.33%
2020-09-30 $0.01B $-0.07B -650.00%
2020-06-30 $0.03B $-0.05B -166.67%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.127B $0.050B
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.298B 9.44
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.439B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.570B 0.00
Arcus Biosciences (RCUS) United States $1.208B 0.00
Biohaven (BHVN) United States $0.950B 0.00
Emergent Biosolutions (EBS) United States $0.405B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.161B 0.00
Enzo Biochem (ENZ) United States $0.109B 0.00
SQZ Biotechnologies (SQZ) United States $0.016B 0.00
Gelesis Holdings (GLS) United States $0.015B 0.00